An Explainable Multimodal Artificial Intelligence Model Integrating Histopathological Microenvironment and EHR Phenotypes for Germline Genetic Testing in Breast Cancer.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Published Date:

Abstract

Genetic testing for pathogenic germline variants is critical for the personalized management of high-risk breast cancers, guiding targeted therapies and cascade testing for at-risk families. In this study, MAIGGT (Multimodal Artificial Intelligence Germline Genetic Testing) is proposed, a deep learning framework that integrates histopathological microenvironment features from whole-slide images with clinical phenotypes from electronic health records for precise prescreening of germline BRCA1/2 mutations. Leveraging a multi-scale Transformer-based deep generative architecture, MAIGGT employs a cross-modal latent representation unification mechanism to capture complementary biological insights from multimodal data. MAIGGT is rigorously validated across three independent cohorts and demonstrated robust performance with areas under receiver operating characteristic curves of 0.925 (95% CI 0.868 - 0.982), 0.845 (95% CI 0.779 - 0.911), and 0.833 (0.788 - 0.878), outperforming single-modality models. Mechanistic interpretability analyses revealed that BRCA1/2-mutated associated tumors may exhibit distinct microenvironment patterns, including increased inflammatory cell infiltration, stromal proliferation and necrosis, and nuclear heterogeneity. By bridging digital pathology with clinical phenotypes, MAIGGT establishes a new paradigm for cost-effective, scalable, and biologically interpretable prescreening of hereditary breast cancer, with the potential to significantly improve the accessibility of genetic testing in routine clinical practice.

Authors

  • Zijian Yang
    Department of Bioengineering, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Changyuan Guo
    Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
  • Jiayi Li
    Department of Statistics, University of California Los Angeles, Los Angeles, CA 90095-1554, USA.
  • Yalun Li
    Department of Health Sciences Research, Mayo Clinic, Scottsdale, AZ.
  • Lei Zhong
    Department of Intensive Care Unit, National Cancer Center/National Clinical Research Center, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Pengming Pu
    Department of Breast Surgical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
  • Tongxuan Shang
    Department of Breast Surgical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
  • Lin Cong
    PingAn Health Technology, Beijing, China.
  • Yongxin Zhou
    Department of Breast Surgical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
  • Guangdong Qiao
    Department of Breast Surgery, the Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, 264000, China.
  • Ziqi Jia
    Department of Thoracic Surgery, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China.
  • Hengyi Xu
    State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
  • Heng Cao
    National Clinical Research Center for Obstetrics and Gynaecology, Cancer Biology Research Centre (Key Laboratory of the Ministry of Education) and Department of Gynaecology and Obstetrics, Tongji Hospital, Wuhan, China.
  • Yansong Huang
    Department of Breast Surgical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
  • Tianyi Liu
    Department of Epidemiology and Biostatistics, School of Public Health, Capital Medical University, Beijing, China.
  • Jian Liang
    Cloud and Smart Industries Group, Tencent, Beijing, China.
  • Jiang Wu
    College of Energy and Mechanical Engineering, Shanghai University of Electric Power, Shanghai 200090, China. Electronic address: wjcfd2002@163.com.
  • Dongxu Ma
    Department of Breast Surgical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
  • Yuchen Liu
    Department of Internal Medicine, Peking Union Medical College Hospital, Beijing, China.
  • Ruijie Zhou
    Department of Breast Surgical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
  • Xiang Wang
    Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.
  • Jianming Ying
    Department of Pathology, National Cancer Center /National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
  • Meng Zhou
    College of Bioinformatics Science and Technology, Harbin Medical University, Harbin, 150081, People's Republic of China. biofomeng@hotmail.com.
  • Jiaqi Liu

Keywords

No keywords available for this article.